Twitter

10/27/2009 - King Pharmaceuticals, Inc. (NYSE:KG) announced that it has licensed the exclusive rights to market and sell CYANOKIT from Merck Sante S.A.S. CYANOKIT is used for the treatment of known or suspected cyanide poisoning, generally caused by smoke inhalation from fires. Chairman, President, and CEO Brian A. Markison said, "CYANOKIT® is well-suited to King's existing line of acute care products," said Brian A. Markison, Chairman, President and CEO. "Our portfolio of antidotes currently serves the emergency medical services community, as well as the U.S. Department of Defense and other federal, state and local agencies. The addition of CYANOKIT® to this portfolio is a natural fit, as we are uniquely positioned to market this antidote in both pre-hospital and hospital settings."

Contact Chip Brian

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at www.TradeTheTrend.com/signup.html